Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Boyraz B, Tajiri R, Alwaqfi RR, Paula AD, Ye Q, G Nielsen P, et al. Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1-CYP2E1 fusions. Histopathology. 2022;81(6):841-846.

Ombres CM, Lestadi I, Putra J. Lingual Choristoma with Gastric Epithelium Revisited. Head Neck Pathol. 2022;16(2):503-506.

Kudalkar EM, Pang C, Haag MM, Pollyea DA, Kamdar M, Xu G, et al. 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. Mol Cytogenet. 2022;15(1):30.

Church AJ, Corson LB, Kao P-, Imamovic-Tuco A, Reidy D, Doan D, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022;28(8):1581-1589.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Marzio A, Kurz E, Sahni JM, Di Feo G, Puccini J, Jiang S, et al. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell. 2022;185(1):169-183.e19.

Rosenstock JL, Joab TM, DeVita MV, Yang Y, Sharma PD, Bijol V. Oxalate nephropathy: a review. Clin Kidney J. 2022;15(2):194-204.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673-685.